Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01538667
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : August 21, 2014
Information provided by (Responsible Party):

Brief Summary:

The purpose of this study is to characterize variability and extent of the deposition of ciprofloxacin in the respiratory tract of healthy subjects in comparison to patients with chronic lung diseases after inhalation of a single 50 mg dry powder dose containing 32 mg active substance. In addition the safety and pharmacokinetics of ciprofloxacin will be evaluated. In this study the radiolabeled substance will be administered and scintigraphy imaging techniques will be used to demonstrate the lung deposition visually. In the healthy subjects an additional pharmacokinetic method is used to calculate lung deposition indirectly based on pharmacokinetic data derived from plasma. For this purpose they will inhale at a separate occasion another dose of ciprofloxacin after having ingested activated charcoal. The latter serves to bind ciprofloxacin which is swallowed down during the inhalation maneuver in the gastrointestinal (GI) tract, thus preventing its uptake into the blood (charcoal block). Safety investigations will focus on local tolerability in the lung.

Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug.

Results from this study will be used to show how the drug is distributed in the human lung.

Condition or disease Intervention/treatment Phase
Respiratory System Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non-blinded, Single Dose, Single Centre Trial to Assess the Pulmonary Deposition as Well as Pharmacokinetics, Safety and Tolerability of 99mTc Labeled Ciprofloxacin When Delivered as a Single Dose From a Dry Powder Inhaler to Healthy Subjects With and Without Charcoal Block and Patients Suffering From Bronchiectasis and COPD
Study Start Date : April 2012
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm 1 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
Experimental: Arm 2 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
Experimental: Arm 3 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
Experimental: Arm 4 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients

Primary Outcome Measures :
  1. Ciprofloxacin pharmacokinetics including lung deposition [ Time Frame: Within 24 hours after treatment ]
    Firstly, scintigraphic imaging, a non-invasive method using a radioactive (99mTc-) label tagged to the formulation, will be used to describe the distribution and deposition of a single inhaled dose of Ciprofloxacin Dry Powder Inhalation (DPI) in the lung quantitatively. Secondly, based on blood sampling over a period of 24 hours after inhalation non-compartmental pharmacokinetic parameters of ciprofloxacin will be calculated to determine the systemic exposure to drug following inhalation of a single 32.5 mg Ciprofloxacin dose.

Secondary Outcome Measures :
  1. Adverse Events collection [ Time Frame: Within 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Inclusion criteria for all subjects:

    • Understanding of the study and written informed consent prior to any study-related procedures
  • Additional inclusion criteria for healthy subjects:

    • Age: 18 to 65 years (inclusive) at screening visit
    • Males
    • Non- or ex-smokers who smoked < 5 pack-years and stopped smoking > 1 year prior to screening visit
    • Results of laboratory tests within the normal ranges; minor deviations are acceptable provided that they are not judged clinically significant by the investigator
  • Additional inclusion criteria for patients with COPD (chronic obstructive pulmonary disease):

    • Age: 40 to 70 years (inclusive) at screening visit
    • Males and females
    • All patients must have a diagnosis of COPD of Stage II or III according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Classification (post-bronchodilator forced expiratory volume in 1 second (FEV1): 80% > FEV1 ≥ 30% of predicted values and a post-bronchodilator FEV1/FVC ≤ 70% (FVC = forced vital capacity)
    • Minimum smoking history of 10 pack-years
  • Additional inclusion criteria for patients with bronchiectasis:

    • Age: 18 to 75 years (inclusive) at screening visit
    • Males and females
    • Diagnosis of bronchiectasis

Exclusion Criteria:

  • Known hypersensitivity, allergy or intolerance to study drug formulation ingredients
  • Febrile illness within 1 week prior to screening visit
  • Concomitant severe diseases (judged by the investigator) or diseases which are contraindications for the use of inhaled ciprofloxacin
  • Use of ciprofloxacin within 30 days before screening visit
  • Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them, e.g. systemic administration of antibiotics which are subject to renal excretion (e.g. beta-lactam antibiotics, levofloxacin, ofloxacin, etc.), furosemide and antacids
  • Donation of more than 450 mL of blood within 4 weeks before screening visit
  • Clinically relevant findings in the ECG
  • Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation
  • Participation in another clinical study less than 8 weeks prior to screening visit
  • Pulmonary exacerbation within the 6 weeks prior to screening
  • History of lung transplant or any lung surgery or on any thoracic surgery waiting list
  • Additional exclusion criteria for healthy subjects

    • Lung function measurements outside normal limits (Normal values: FEV1/FVC > 70% and FEV1 and FVC > 80% of predicted)
  • Additional exclusion criteria for patients

    • Regular use of daytime oxygen therapy
    • Diagnosis of bronchial asthma
    • Diagnosis of clinically evident bronchiectasis (COPD patients)
    • Total blood eosinophil count >/= 600/mm3.
    • Completion of a pulmonary rehabilitation program in the six weeks prior to screening visit or current participation in a pulmonary rehabilitation program
    • Change in dose or type of any medications within 4 weeks prior to the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01538667

Gauting, Bayern, Germany, 82131
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer Identifier: NCT01538667     History of Changes
Other Study ID Numbers: 11523
2011-000342-38 ( EudraCT Number )
First Posted: February 24, 2012    Key Record Dates
Last Update Posted: August 21, 2014
Last Verified: August 2014

Keywords provided by Bayer:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Protective Agents
Physiological Effects of Drugs